The Conversation (0)
Sirona Biochem Corp . (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces the advancement of 20 antiviral compounds to In Vitro testing. The compounds will be shipped to the Utah State University's Institute of Antiviral Research for evaluation against the SARS-CoV-2 virus (COVID-19).
Sirona's French subsidiary, TFChem, has created a novel and patentable library of 20 compounds that are designed to target the COVID-19 virus by targeting the host cell and not the virus itself. When a virus enters a cell, it induces a "cytopathic effect" which refers to structural changes in the host cell, that allow the virus to replicate. In SARS-CoV-2, the virus causes plaque-like effects in the human cells of the lung. Mechanisms such as cell fusion, apoptosis (death) and destruction of epithelium integrity are all observed in the plaque regions (Nature Communications, 2020, https://www.nature.com/articles/s41467-020-17796-z ). Sirona's antiviral compounds are intended to prevent the cytopathic effect from occurring.
The results will be completed in approximately 6 weeks.
"Since the compounds are designed to target the host cell and not the virus itself, we have a unique approach that is based on our proprietary technology . We have seen the number of variants that the SARS-CoV-2 virus has. It will continue to mutate, creating new strains, so there is a strong need for compounds like these that are not targeted to a specific virus," said Dr. Howard Verrico , CEO of Sirona Biochem. "It is now time to push this program as quickly as possible, adding to a robust and valuable pipeline that will attract the right kind of partners. For this project, we have already been in preliminary discussion with a company that has expertise in antiviral clinical trials. The results from these preliminary studies will be key to moving forward with potential partners in 2022."
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
*Unaudited management estimate. Final balance will be determined post-completion.